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PPARc activity in subcutaneous abdominal fat tissue
and fat mass gain during short-term overfeeding
AMCP Joosen1, AHF Bakker1, AHG Zorenc1, S Kersten2, P Schrauwen1 and KR Westerterp1
1Department of Human Biology, Maastricht University, Maastricht, The Netherlands and 2Division of Human Nutrition,
Wageningen University, Wageningen, The Netherlands
Objective: As the peroxisome proliferator-activated receptor g (PPARg) plays a central role in fat mass regulation, we investigated
whether initial subcutaneous PPARg activity is related to fat mass generation during overfeeding.
Subjects: Fourteen healthy female subjects (age 2574 years, BMI 22.172.3 kg/m2).
Design and measurements: Subjects were overfed with a diet supplying 50% more energy than baseline energy requirements
for 14 days. Fasting blood samples were analyzed for leptin, insulin and glucose. Fasting subcutaneous abdominal fat biopsies
were obtained for analysis of PPARg1, PPARg2, aP2 and UCP2 mRNAs.
Results: Initial PPARg1 and 2, aP2 and UCP2 mRNAs were not related to fat gain (P40.12). However, PPARg1, PPARg2 and aP2
mRNA changes were positively related to changes in plasma leptin (Po0.05) and, except aP2 (P¼ 0.06), to fat gain (Po0.05).
PPARg and aP2 mRNA changes were positively related (Po0.01), indicating that PPARg mRNA levels reflected PPARg activity.
Conclusion: These data suggest that the ability to increase PPARg activity might be involved in the susceptibility to gain weight
during a positive energy balance.
International Journal of Obesity (2006) 30, 302–307. doi:10.1038/sj.ijo.0803146; published online 25 October 2005
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Introduction
Obesity is characterized by an excessive fat mass. However,
within a normal weight population also, large differences in
fat mass are observed. Overfeeding identical twins with a
fixed amount of energy resulted in at least three-fold more
variance in gains in body weight and fat mass between pairs
than within pairs,1 which indicates that body weight and
composition are largely genetically controlled. An interac-
tion between environmental factors (e.g. food intake) and
genes involved in adipose tissue metabolism may therefore
determine the susceptibility to obesity.
The peroxisome proliferator-activated receptor g (PPARg)
has been shown to be both sufficient and obligatory for fat
generation.2 In addition, PPARg has an important role in fat
storage (leading to an increased adipocyte volume) and
metabolism in differentiated adipocytes by stimulating the
expression of adipocyte-specific genes.2 PPARg is a member
of the nuclear hormone receptor superfamily and is
expressed as two isoforms, PPARg1 and PPARg2, generated
from the same gene by alternative promoter usage and
alternative splicing. Both isoforms are expressed at high
levels in adipose tissue.3–5 PPARg activity requires the
formation of heterodimers and the binding of ligands. These
heterodimers are formed with another nuclear hormone
receptor, the retinoid X receptor (RXR), which binds to PPAR
response elements in the promoter region of target genes and
activates DNA transcription upon ligand binding.4 Several
ligands and agonists of PPARg are known, including certain
polyunsaturated fatty acids and eicosanoids and the anti-
diabetic thiazolidinedione (TZD) class of drugs.6
As PPARg plays a central role in fat mass regulation, we
investigated whether initial PPARg activity is related to fat
mass gain during overfeeding. In this context, it is important
to know whether increased PPARg mRNA levels reflect an
increase in PPARg activity. The adipocyte-specific fatty acid-
binding protein (aP2) is primary a PPARg response gene and
is therefore commonly used as an adipocyte-specific marker
in vitro.7,8 In addition, PPARg is involved in the regulation of
the uncoupling protein 2 (UCP2) as PPARg agonists are
shown to increase UCP2 expression in adipose tissue.9–11
UCP2 mRNA levels are reduced in adipose tissue from obese
compared to lean persons,12 which suggests a role for UCP2
in obesity by influencing energy metabolism although a
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Male and female subjects were recruited through advertise-
ments in the university and the university hospital. However
only female subjects responded, therefore 14 female subjects,
aged 19–36 years, participated in the study. Characteristics of
the subjects are shown in Table 1. Selection criteria included
being healthy, between the age of 18 and 40 years,
Caucasian, non- or light (o10 cigarettes/day) smoker, with
a BMI between 18.5 and 27kg/m2 and weight stable (body
weight changes p2kg) for at least a year at the start of the
study. Before participating in the study, subjects were
medically screened by a detailed health questionnaire, only
subjects in good health were included. All subjects received
verbal and written information and signed a written consent
form. The study was approved by the Ethics Committee of
Maastricht University.
Experimental design
The study enclosed a 7-day baseline period (days 1–8) and a
14-day overfeeding period (days 8–22). During the baseline
period subjects chose their diets from a variety of food items
provided daily in weighed food packages, bringing back the
leftovers the next day, for calculation of habitual energy
intake. When subjects had not been in energy balance (i.e.
body weight changed from day 1 to day 8), baseline energy
requirements were calculated from basal metabolic rate
and physical activity level. During the overfeeding period,
diets contained 50% more energy than the baseline energy
requirements (14.871.6MJ/day or a total of 207.2721.6MJ).
The excess energy intake was introduced gradually to allow
the bowels to adjust to the increased amount of food.
Overfeeding diets provided 7% of energy from protein, 40%
from fat and 53% from carbohydrates (Dutch food composi-
tion table, Komeet, version 2.0d, 1996, B ware Nutrition
Software). All foods and drinks were provided daily in
weighed food packages while subjects consumed dinner at
the university. Alcohol consumption was not allowed during
the study. Body weight was measured on days 1, 8 and 22.
Body composition was measured on days 8 and 22 and on
the same days blood samples and fat biopsies were taken.
Subjects maintained their normal lifestyles (i.e. work,
education, sports participation) throughout the study.
Procedures
Anthropometry and body composition. Measurements were
carried out in the morning after voiding and before breakfast.
Body weight and height were measured to the nearest 0.01kg
and 0.1 cm, respectively. Body mass index (BMI, kg/m2) was
calculated as body weight (kg) divided by height (m) squared.
Body composition was estimated using hydrodensitometry
and isotope dilution. Body density was determined by
underwater weighing with simultaneous measurement of
residual lung volume with the helium dilution technique.
Total body water (TBW) was determined with deuterium
dilution following the Maastricht protocol.13 Body composi-
tion was calculated from body density and TBW using the
three-compartment model of Siri.14
Plasma glucose, insulin and leptin. After an overnight fast,
blood samples were obtained and mixed with citrate to
prevent clotting. Plasma was obtained by centrifugation
(41C, 3000 rpm, 10min), frozen in liquid nitrogen and stored
at 801C until analysis of concentrations of glucose
(hexokinase method, Glucose HK 125 kit, ABX diagnostics,
Montpellier, France), insulin (ELISA, Mercodia, Uppsala,
Sweden) and leptin (double-antibody RIA, human leptin
specific RIA kit, Linco Research Inc., St Charles, USA).
Fat biopsy. Abdominal subcutaneous fat biopsies
were obtained by needle liposuction under local anesthesia
(lidocain 2% with adrenalin 1:80 000, AstraZeneca BV,
Nederland) after an overnight fast. The tissue was immedi-
ately washed in cold saline, homogenized in 1ml
Trizol (Gibco BRL, Life Technologies) in a mini-beadbeater
(Biospec Products, Bartlesville, OK, USA), frozen in liquid
nitrogen and stored at 801C until RNA extraction. Total
RNA was isolated using the method of Chomczynski and
Sacchi15 and 10 mg glycogen was added to each sample.
Extracted RNA was quantified and assessed for purity by UV
spectrophotometry.
Quantitation of PPARg1, PPARg2 and aP2 mRNA expression by
real-time RT-PCR. cDNA was synthesized from 500ng RNA
in a volume of 20 ml containing 2 ml RT buffer (Sensiscript
RTkit, Qiagen, Hilden, Germany), 2ml dNTPs, 1 ml oligo (dT)
primer, 0.25 ml RNase inhibitor and 1ml reverse transcriptase
(Sensiscript RTkit, Qiagen). The RT reaction was performed at
371C for 60min.
PCR reactions were performed in a final volume of 25 ml
containing 0.2 SYBR Green/fluorescein in DMSO (5
SYBR Green/0.25 mM fluorescein), 1 Taq buffer, 0.02U/ml
Taq polymerase, 0.2mM dNTPs, 3mM MgCl2, 0.6 pmol/ml of
each primer and 25ng/ml cDNA. The PCR program was at
Table 1 Baseline characteristics of the 14 female subjects
Mean s.d.
Age (years) 25 4
Height (m) 1.72 0.06
Body weight (kg) 64.8 7.0
Body mass index (kg/m2) 22.1 2.3
Body fat (%) 27.5 4.4
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941C for 2min, followed by 45 cycles of 941C for 15 s and
601C for 1min. After every cycle, the fluorescence of SYBR
Green was measured, which represents the amount of
double-stranded DNA amplified to that point in the PCR.
Subsequently, melt curve analysis (451C for 5min, 100 cycles
of 651C for 10 s, þ0.31C after cycle 2) indicated specific
product for each pair of primers. The primer sequences were
as follows: PPARg1 forward 50-AAGGCCATTTTCTCAAACG
A-30, reverse 50-AGGAGTGGGAGTGGTCT-TCC-30; PPARg2
forward 50-CCATGCTGTTATGGGTG-AAA-30, reverse 50-
TCAAAGGAGTGGGAGTGGTC-30; aP2 forward 50-GCATTC
CAC-CACCAGTTTATC-30, reverse 50-CAGGAAAGTCAAGAG
CACCAT-30; b-actin forward 50-AGAAAATCTGGCACCA
CACC-30, reverse 50-AGAGGCGTACAGGGATA-GCA-30. For
target and housekeeping genes, standard curves were created
from a specific PCR product. To account for differences in
RNA loading, target mRNA was expressed relative to b-actin
mRNA. The mRNA concentration of b-actin was not different
between baseline and overfeeding (109767 and 88787,
respectively, based on photospectrometry, P¼0.48). The
threshold cycle (CT) is the cycle number at which the
fluorescence is first recorded, statistically significant above
background. The CT always occurs during the exponential
phase of the amplification and thus shows a negative linear
relationship with the log cDNA: the more cDNA present at
the beginning of the PCR, the fewer number of cycles it takes
to reach the CT. The PCR amplification efficiencies of the
target and housekeeping genes were similar and therefore
the amount of target mRNA relative to the amount of b-actin
mRNA in each sample was calculated as follows: DCT¼CT
(target)CT (b-actin), relative expression level¼2DCT .
Quantitation of UCP2 mRNA expression by RT-competitive
PCR. Total RNA (0.2 mg) was reverse transcribed as described
above using Tth DNA polymerase and specific primers.
Target cDNA (0.2 mg) was coamplified with known amounts
of the target cDNA competitor in the same tube. The PCR
reaction was performed with 50-ATGGACGCCTACAGAAC
CAT-30 as sense primer and 50-ATAGGTGACGAACATCAC
CACG-30 as antisense primer, and specific competitor DNA
was obtained by the deletion of 55bp from a 290-nt long
UCP2 cDNA fragment. The PCR program was at 941C for
3min, 35 cycles of 941C for 1min, 571C for 45 s and 721C
for 2min, followed by 741C for 5min. PCR products were
analyzed with the ALF sequencer. The amount of UCP2
mRNA, expressed as amol/mg total RNA, was obtained from
the point where the initial amount of target cDNA
corresponds to the initial amount of competitor (log density
ratio competitor/target cDNA¼0).
Statistical analysis
Results are presented as means7s.d.’s unless otherwise
specified. The nonparametric paired Wilcoxon signed rank
test (two-sided) was used to test the effect of the overfeeding
on the parameters. Significance of correlations was tested
with the nonparametric Spearman rank correlation (rS).
Po0.05 was considered as statistically significant. StatView
statistical software (1992–1998, SAS Institute Inc., NC, USA)
was used for the analysis.
Results
Overfeeding resulted in a mean body weight gain of
1.4570.86 kg (Po0.0001), with a range from 0.19 to
3.00 kg. Fat mass increased by 1.0570.75 kg (Po0.001)
ranging from 0.12 to 2.65 kg.
Mean fasting plasma glucose, insulin and leptin concen-
trations before and after overfeeding are shown in Table 2.
Changes in plasma insulin and leptin concentrations were
positively correlated (rS¼0.77, Po0.01). Changes in plasma
leptin concentrations were related to fat mass gain (rS¼0.62,
P¼0.02), changes in plasma insulin concentrations were not
statistically significant related to fat mass gain (P¼0.08).
Table 3 shows the median fasting mRNA levels of PPARg1
and 2, aP2 and UCP2 in subcutaneous abdominal adipose
tissue before and after overfeeding. PPARg1 and 2 and aP2
mRNA levels at baseline were neither related to the initial
fat mass (P40.30) nor to the fat mass gain (P40.12). UCP2
mRNA levels at baseline tended to be negatively related to
the initial fat mass (P¼0.06), but were not associated with
fat mass gain (P¼0.79). However, the increase in fat mass
with overfeeding was related to changes in PPARg1 (rS¼0.71,
P¼0.01; Figure 1a) and PPARg2 (rS¼0.64, P¼0.02; Figure 1b)
mRNA with a trend towards a relation with changes in aP2
(rS¼0.52, P¼0.06; Figure 1c) mRNA. Similar results were
Table 2 Fasting plasma concentrations of glucose, insulin and leptin at
baseline and after overfeeding
Baseline Overfeeding
Mean s.d. Mean s.d.
Glucose (mmol/l) 4.4 0.2 4.4 0.3
Insulin (mU/ml) 5.7 1.7 7.0 2.6
Leptin (ng/ml) 5.9 2.5 10.5a 5.3
aSignificantly different from baseline using Wilcoxon’s paired signed rank test
(P¼0.001).
Table 3 mRNA levels of PPARg1, PPARg2, aP2 and UCP2 in subcutaneous
abdominal adipose tissue at baseline and after overfeeding
Baseline Overfeeding
Median Range Median Range
PPARg1/b-actin mRNA 1.55 (0.28–15.35) 1.96 (0.68–10.06)
PPARg2/b-actin mRNA 0.27 (0.11–4.08) 0.54 (0.22–2.04)
aP2/b-actin mRNA 22.27 (3.39–362.04) 27.94 (10.34–76.11)
UCP2 (amol/mg RNA) 0.35 (0.01–2.18) 0.32 (0.05–1.54)
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obtained when fat mass gain was expressed as percent
change of intial fat mass (data not shown). The increase in
fat mass was not related to changes in UCP2 mRNA levels
(P¼0.23) and changes in PPARg2 and UCP2 mRNA levels
were not statistically significantly related (P¼0.08).
Interestingly, high initial PPARg1 and 2 mRNA levels
tended to relate to smaller changes in expression of these
genes (rS¼0.54, P¼0.05 for PPARg1; rS¼0.48, P¼0.06 for
PPARg2). Nevertheless, PPARg1 and 2 mRNA levels were
related to aP2 mRNA levels at baseline and after overfeeding
(rS¼0.56 to 0.85, Po0.05) and changes in the expression of
PPARg1 and 2 expression were positively related to changes
in aP2 expression (rS¼0.88 and 0.74 respectively, Po0.01;
Figure 2), indicating that PPARg activity is in proportion
to the PPARg gene expression and to changes in gene
expression.
Changes in plasma leptin concentrations were positively
related to changes in mRNA levels of PPARg1, PPARg2
and aP2 (rS¼ 0.57 to 0.71, Po0.02), but these correlations
disappeared after correction of changes in leptin for fat
mass gain (P40.45), which indicates that the changes
in gene expression were directly associated with changes in
fat mass.
There was a positive relation between changes in plasma
insulin concentrations and PPARg2 mRNA levels (rS¼0.70,
P¼0.01), but there was no statistically significant relation
with PPARg1, aP2 and UCP2 (P40.06) mRNA levels.
Discussion
The present study aimed to investigate whether the initial
PPARg activity is related to fat mass generation during short-
term overfeeding. The initial PPARg gene expression was not
significantly related to fat mass gain during overfeeding, but
the change in PPARg expression was positively correlated to
fat mass gain. We measured the two PPARg isoforms, PPARg1
and PPARg2, separately. Both isoforms can stimulate adipo-
genesis but there is evidence that at low ligand concentra-
tions, PPARg2 has a greater ability to stimulate adipogenesis.5
Figure 1 Relationship between changes in PPARg1 (a), PPARg2 (b) and aP2
(c) mRNA levels and fat mass gain.
Figure 2 Relationship between changes in PPARg1 (K) and PPARg2 (J)
mRNA levels and changes in aP2 mRNA levels.
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In this study, we did not see different activities of
both isoforms: both PPARg1 and 2 gene expressions
were related to the expression of aP2 and the gene
expressions were induced to the same extent. AP2 mRNA
levels are primary regulated by PPARg and are shown to
be a quantitative measure of PPARg activity,7,8 therefore
PPARg mRNA levels did reflect PPARg activity in vivo. This
suggests that the ability to increase PPARg activity might
be involved in the susceptibility to gain weight during
overfeeding.
In a population of Finnish men and women, the common
Pro12Ala polymorphism in the PPARg2 gene is associated
with lower BMI.16 The mutant PPARg2 protein showed an
impaired ability to mediate TZD-induced adipogenesis,16,17
therefore the association with lower BMI is likely to be the
result of the lower transcriptional capacity of the Ala variant
of PPARg2.16 The mRNA expression of PPARg2 target genes in
the adipose tissue of morbid obese subjects did not seem
to be influenced by the Pro12Ala polymorphism,18 which
suggests that particular environmental factors, like diet,
influence the contribution of the genotype to the develop-
ment of obesity.
The study included healthy nonobese and normoglycemic
female subjects. Fasting plasma glucose was the same before
and after the overfeeding period, and although there were
large interindividual differences, mean fasting plasma in-
sulin did not change significantly. An increased PPARg
activity, leading to adipocyte differentiation, results in an
increase in insulin sensitivity.19 Indeed, we found a positive
relation between changes in plasma insulin and PPARg2
mRNA, and a trend towards a relation with PPARg1 mRNA.
Changes in plasma insulin tended to be related to fat mass
gain. This effect of short-term overfeeding was in accordance
with the observed increase in PPARg mRNA levels in
subcutaneous abdominal fat tissue after a 3h insulin
infusion20 and the induction of PPARg mRNA in isolated
human adipocytes by insulin.3
The weight gain period in this study was 2 weeks and
the extent of induction of PPARg expression was positively
related to fat gain over this interval. We can only speculate
on the relation in the longer term. Fat mass is determined by
the number of fat cells and by the continuous uptake and
release of energy by the fat cell. PPARg is required for the
formation of new fat cells and plays a major role in fat
storage and metabolism. Therefore, both slow and fast
adaptation of the PPARg expression to a positive energy
balance will lead to an increased fat mass but the time span
may vary.
Another factor in determining fat mass gain in response to
overfeeding is the thermogenic capacity of adipose tissue.
UCP2 is homologue of the brown adipose tissue UCP1,
which uncouples proton entry in the mitochondrial matrix
from energy production, thereby dissipating energy as heat.
The expression of UCP2 is reduced in adipose tissue of obese
vs lean subjects.12 In a population-based sample from the
same geographic area, a common UCP2 polymorphism
could account for 15% of the obesity prevalence,12 and
genetic variation at the UCP2 locus is associated with energy
expenditure in Pima Indians.21 Together, these observations
suggest a role for UCP2 in obesity by influencing energy
metabolism although a specific uncoupling function has not
been confirmed in humans.10 In addition, UCP2 is at least in
part regulated through PPARg as PPARg agonists increases
adipose UCP2 expression.9–11 Direct evidence was provided
by the observation that a 5h infusion with nonesterified
fatty acids upregulated UCP2 and PPARg mRNA levels in
subcutaneous adipose tissue.22 However, in the present
study, we found no effect of overfeeding on UCP2 mRNA
and we found no statistically significant relation between
changes in PPARg and UCP2 mRNA levels. Changes in
plasma insulin were not related to changes in UCP2 mRNA
either. This suggests that the response of UCP2 to over-
feeding is not a major determinant of fat mass gain, although
again, the study period might have influenced these results.
In conclusion, these data suggest that the ability to
increase PPARg activity might be involved in the suscept-
ibility to gain weight during a positive energy balance.
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